BC Extra | Mar 7, 2019
Clinical News

Allergan's rapastinel misses as adjunct depression therapy

Allergan said late Wednesday that rapastinel as adjunctive therapy missed the primary endpoint in three Phase III trials for the acute treatment of major depressive disorder (MDD). Allergan plc (NYSE:AGN) is also conducting a Phase...
BC Extra | Feb 15, 2018
Company News

Management tracks: bluebird, Sangamo

Gene therapy company bluebird bio Inc. (NASDAQ:BLUE) promoted Alison Finger to chief commercial officer from SVP of marketing and product launch. Gene editing company Sangamo Therapeutics Inc. (NASDAQ:SGMO) hired Heather Turner as SVP and general...
BioCentury | Dec 22, 2017
Finance

Modulating mechanism

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials...
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

Naurex Inc. spinout Aptinyx Inc. has a discovery platform and preclinical pipeline of oral small molecule NMDA receptor modulators for CNS disorders that could enhance synaptic plasticity and avoid the adverse events associated with NMDA...
BioCentury | May 16, 2016
Finance

Naurex's New Leaf

With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million series A round last week for...
BC Extra | May 11, 2016
Top Story

CNS company Aptinyx raises $65M series A

Aptinyx Inc. (Evanston, Ill.) raised a tranched $65 million series A round led by New Leaf Venture Partners. New investors Frazier Healthcare Partners , Longitude Capital and Osage University Partners also participated alongside existing investors Adams...
BioCentury | Nov 9, 2015
Strategy

Pfizer's growth spurt

Eighteen months ago, flat-to-flagging growth across Pfizer Inc .'s innovative and established products businesses suggested the pharma needed a major acquisition to shore up the units before it could move forward with a much-discussed potential...
BC Week In Review | Sep 21, 2015
Company News

Aptinyx, Allergan deal

Newco Aptinyx and Allergan will collaborate on the discovery and preclinical development of oral small molecule NMDA receptor modulators to treat psychiatric and neurologic disorders. Allergan has the right to in-license an undisclosed number of...
BC Week In Review | Sep 21, 2015
Company News

Naurex, Allergan deal

Allergan completed its acquisition of Naurex for $560 million up front, plus undisclosed R&D success-based and sales-threshold milestone payments (see BioCentury, Aug. 3). Naurex Inc. , Evanston, Ill.   Allergan plc (NYSE:AGN), Dublin, Ireland   Business:...
BC Extra | Sep 17, 2015
Company News

Former Naurex execs launch Aptinyx

A team of former Naurex Inc. executives have spun out the company's discovery platform and preclinical pipeline into Aptinyx Inc. (Evanston, Ill.), a newco focused on developing treatments for psychiatric and neurologic disorders. Aptinyx President...
Items per page:
1 - 10 of 43
BC Extra | Mar 7, 2019
Clinical News

Allergan's rapastinel misses as adjunct depression therapy

Allergan said late Wednesday that rapastinel as adjunctive therapy missed the primary endpoint in three Phase III trials for the acute treatment of major depressive disorder (MDD). Allergan plc (NYSE:AGN) is also conducting a Phase...
BC Extra | Feb 15, 2018
Company News

Management tracks: bluebird, Sangamo

Gene therapy company bluebird bio Inc. (NASDAQ:BLUE) promoted Alison Finger to chief commercial officer from SVP of marketing and product launch. Gene editing company Sangamo Therapeutics Inc. (NASDAQ:SGMO) hired Heather Turner as SVP and general...
BioCentury | Dec 22, 2017
Finance

Modulating mechanism

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials...
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

Naurex Inc. spinout Aptinyx Inc. has a discovery platform and preclinical pipeline of oral small molecule NMDA receptor modulators for CNS disorders that could enhance synaptic plasticity and avoid the adverse events associated with NMDA...
BioCentury | May 16, 2016
Finance

Naurex's New Leaf

With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million series A round last week for...
BC Extra | May 11, 2016
Top Story

CNS company Aptinyx raises $65M series A

Aptinyx Inc. (Evanston, Ill.) raised a tranched $65 million series A round led by New Leaf Venture Partners. New investors Frazier Healthcare Partners , Longitude Capital and Osage University Partners also participated alongside existing investors Adams...
BioCentury | Nov 9, 2015
Strategy

Pfizer's growth spurt

Eighteen months ago, flat-to-flagging growth across Pfizer Inc .'s innovative and established products businesses suggested the pharma needed a major acquisition to shore up the units before it could move forward with a much-discussed potential...
BC Week In Review | Sep 21, 2015
Company News

Aptinyx, Allergan deal

Newco Aptinyx and Allergan will collaborate on the discovery and preclinical development of oral small molecule NMDA receptor modulators to treat psychiatric and neurologic disorders. Allergan has the right to in-license an undisclosed number of...
BC Week In Review | Sep 21, 2015
Company News

Naurex, Allergan deal

Allergan completed its acquisition of Naurex for $560 million up front, plus undisclosed R&D success-based and sales-threshold milestone payments (see BioCentury, Aug. 3). Naurex Inc. , Evanston, Ill.   Allergan plc (NYSE:AGN), Dublin, Ireland   Business:...
BC Extra | Sep 17, 2015
Company News

Former Naurex execs launch Aptinyx

A team of former Naurex Inc. executives have spun out the company's discovery platform and preclinical pipeline into Aptinyx Inc. (Evanston, Ill.), a newco focused on developing treatments for psychiatric and neurologic disorders. Aptinyx President...
Items per page:
1 - 10 of 43